Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Leads $8M Financing Round in GenoLogics

Premium

Laboratory information management system software company GenoLogics said last week that it has closed an $8 million funding round led by Illumina, a new investor in the company.

The financing will be used to develop products for clinical applications and new desktop sequencing systems, and also to expand sales and marketing functions. As part of the deal, Illumina's senior vice president and chief commercial officer, Tristan Orpin, will join GenoLogics' board of directors.

The GenoLogics investment "will benefit our mutual sequencing customers," Orpin said in a statement.

The investment builds on a previous agreement the companies struck up earlier this year to co-sell GenoLogics' LIMS (IS 2/8/2011). In September, GenoLogics released a preconfigured package for Illumina sequencing.

According to GenoLogics CEO Michael Ball, the investment will help customers "overcome some of the most challenging barriers to next-generation sequencing adoption, namely data management."

Additional details of the financing round were not disclosed.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.